FDA Approves TECELRA for Synovial Sarcoma Treatment

The American Society for Transplantation and Cellular Therapy (ASTCT®) celebrates the FDA's accelerated approval of TECELRA® (afamitresgene autoleucel). This new therapy is for adults with unresectable or metastatic synovial sarcoma who have undergone prior chemotherapy. TECELRA marks a major advancement in cellular therapy for this rare, soft tissue cancer.

Developed by Adaptimmune Therapeutics plc, TECELRA is the first engineered cell therapy approved in the U.S. for a solid tumor cancer. It is also the first new treatment for synovial sarcoma in over a decade. The approval is based on clinical trial results showing a 43% overall response rate and a 4.5% complete response rate.

ASTCT President Corey Cutler, MD, MPH, FRCPC, emphasized the collaborative efforts behind this achievement. ASTCT has long supported innovation in cellular therapies to improve patient outcomes. TECELRA's approval is expected to significantly impact the synovial sarcoma community.

Healthcare professionals and patients seeking more information on TECELRA are encouraged to contact Adaptimmune directly.